Pentacyclic triterpenic acid from Boswellia serrata oleogum resin with selective 5-lipoxygenase inhibition and pleiotropic anti-inflammatory activity
A family of ursane- and oleanane-type pentacyclic triterpenes isolated from Boswellia serrata frankincense resin, distinguished by noncompetitive allosteric inhibition of 5-lipoxygenase and convergent anti-inflammatory activity through NF-kappaB suppression, topoisomerase inhibition, and leukotriene biosynthesis blockade.
Abstract
Boswellic acids are a family of pentacyclic triterpenic acids isolated from the oleogum resin (frankincense) of Boswellia serrata and related species (B. carterii, B. sacra, B. papyrifera) that have been used in Ayurvedic medicine for centuries under the name Salai guggal and are now recognized as pharmacologically active anti-inflammatory agents with a distinct mechanism of action centered on selective, noncompetitive, allosteric inhibition of 5-lipoxygenase (5-LOX). The family comprises four principal bioactive congeners: beta-boswellic acid (beta-BA), 11-keto-beta-boswellic acid (KBA), 3-O-acetyl-beta-boswellic acid (ABA), and 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), with AKBA representing the most potent 5-LOX inhibitor (IC50 approximately 1.5 micromolar in human neutrophils) and the primary pharmacologically characterized congener. The 5-LOX inhibition by AKBA proceeds through an allosteric, nonredox, noncompetitive mechanism that is unique among clinically studied leukotriene synthesis inhibitors and distinguishes the boswellic acid class from both the redox-type 5-LOX inhibitors (zileuton) and the competitive cysteinyl leukotriene receptor antagonists (montelukast, zafirlukast). Beyond 5-LOX inhibition, boswellic acids exert convergent anti-inflammatory activity through suppression of NF-kappaB signaling via direct inhibition of IkappaB kinases (IKKalpha and IKKbeta), inhibition of human leukocyte elastase, inhibition of topoisomerases I and IIalpha, modulation of complement system activation, and suppression of proinflammatory cytokine release including tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6. Pharmacokinetics in humans are characterized by poor oral bioavailability of the keto-boswellic acids (KBA and AKBA) attributable to extensive first-pass hepatic metabolism via CYP3A4-mediated hydroxylation and carboxylesterase 2-mediated deacetylation, with plasma elimination half-lives of approximately 6 hours. Concomitant administration with a lipid-rich meal substantially improves absorption. Clinical evidence from randomized controlled trials supports efficacy in osteoarthritis (pain reduction and functional improvement at 100 to 250 mg AKBA-enriched extract daily), bronchial asthma (improvement in 70 percent of patients at 300 mg three times daily), inflammatory bowel disease (Crohn’s disease and ulcerative colitis, with response rates comparable to mesalazine), and radiation-induced cerebral edema (greater than 75 percent edema reduction in 60 percent of patients at 4200 mg daily). The compound class is generally well tolerated, with the principal adverse events being mild gastrointestinal discomfort (nausea, acid reflux, diarrhea) and rare allergic dermatitis. This monograph reviews the chemistry, structural pharmacology, and biosynthesis of the boswellic acid family; the multi-target mechanism of action in molecular detail; the comprehensive human pharmacokinetic record including bioavailability enhancement strategies; the clinical evidence base across osteoarthritis, asthma, inflammatory bowel disease, cerebral edema, and oncology-supportive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative anti-inflammatory natural compounds against boswellic acids on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Sigma-1 receptor agonist and mixed muscarinic receptor modulator (aminotetrahydrofuran derivative)
An orally bioavailable aminotetrahydrofuran derivative developed by Anavex Life Sciences as a sigma-1 receptor agonist with muscarinic receptor co-activity, investigated for disease modification in Alzheimer’s disease, Rett syndrome, Parkinson’s disease dementia, and other neurodegenerative and neurodevelopmental conditions.
Abstract
Blarcamesine (ANAVEX 2-73; tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine) is a small-molecule sigma-1 receptor (SIGMAR1) agonist and mixed muscarinic acetylcholine receptor modulator that has advanced through Phase 2b/3 clinical development for early Alzheimer’s disease, Phase 3 for adult Rett syndrome, Phase 2 for Parkinson’s disease dementia, and Phase 2/3 for pediatric Rett syndrome. The compound was first characterized pharmacologically by Villard, Espallergues, Keller, Vamvakides, and Maurice (2011) as a novel aminotetrahydrofuran derivative with anti-amnesic and neuroprotective activity mediated through dual engagement of sigma-1 and muscarinic acetylcholine receptors. The sigma-1 receptor is an endoplasmic reticulum chaperone protein localized at mitochondria-associated endoplasmic reticulum membranes (MAMs) that modulates calcium homeostasis, endoplasmic reticulum stress responses, mitochondrial function, autophagy, and neuroinflammation. Activation of SIGMAR1 by blarcamesine restores cellular proteostasis, reduces oxidative stress through suppression of reactive oxygen species, and promotes neuroplasticity through downstream modulation of brain-derived neurotrophic factor and glutamate signaling. In preclinical models, blarcamesine has demonstrated anti-amnesic activity in scopolamine- and dizocilpine-induced learning impairment paradigms, neuroprotection in the amyloid-beta(25-35) peptide injection mouse model of Alzheimer’s disease (blocking both cognitive impairment and hippocampal oxidative stress), amelioration of motor, sensory, and autonomic phenotypes in the Mecp2 mouse model of Rett syndrome, and dose-dependent sigma-1 receptor occupancy confirmed by positron emission tomography with the selective ligand [18F]FTC-146. The pivotal ANAVEX2-73-AD-004 Phase 2b/3 randomized, double-blind, placebo-controlled trial enrolled 508 patients with early Alzheimer’s disease across 52 centers in five countries and demonstrated that oral blarcamesine at 50 mg and 30 mg daily significantly slowed cognitive decline on the primary endpoint ADAS-Cog13 at 48 weeks (38.5% and 34.6% slowing versus placebo, respectively; P = 0.021 and P = 0.026) [1]. Co-primary analysis showed significant benefit on CDR-SB. Volumetric magnetic resonance imaging demonstrated significant reduction of whole brain atrophy by 37.6%, total grey matter atrophy by 63.5%, and lateral ventricular enlargement by 25.1% versus placebo. Plasma amyloid-beta 42/40 ratio increased significantly in the blarcamesine group (P = 0.048). Open-label extension data through four years of continuous treatment demonstrated sustained benefit on ADAS-Cog13 and ADCS-ADL, with a delayed-start analysis suggesting importance of early treatment initiation. The AVATAR Phase 3 trial in 33 adult patients with Rett syndrome (MECP2 mutation-positive) met primary (RSBQ AUC, P = 0.037; Cohen’s d = 1.91) and secondary (ADAMS, P = 0.010; CGI-I, P = 0.037) efficacy endpoints on once-daily oral dosing of up to 30 mg [2]. A proof-of-concept Phase 2 trial in 132 patients with Parkinson’s disease dementia showed dose-dependent cognitive improvement on the CDR computerized assessment system and improvement on MDS-UPDRS total score at 14 weeks [3]. The EXCELLENCE Phase 2/3 pediatric Rett syndrome trial in 92 patients showed numerical improvement in RSBQ but did not achieve statistical separation from placebo, possibly due to a high placebo response rate [4]. The safety profile across clinical programs is characterized by predominantly mild-to-moderate adverse events concentrated during the initial dose titration period. The most common treatment-emergent adverse events are dizziness (approximately 36% of treated patients in the Alzheimer’s disease program), confusional state (approximately 14%), balance disorder, and fatigue; these are generally transient (resolving within 7 to 11 days), manageable by titration schedule adjustment, and not associated with serious or life-threatening sequelae. No neuroimaging-related adverse events (such as amyloid-related imaging abnormalities) have been reported. Long-term safety data through four years of continuous dosing have not revealed new safety signals. The European Medicines Agency accepted a Marketing Authorization Application for blarcamesine in Alzheimer’s disease in December 2024, but the Committee for Medicinal Products for Human Use issued a negative opinion in December 2025 on grounds of insufficient demonstration of efficacy in patients without SIGMAR1 gene mutations and concerns regarding tolerability-driven treatment discontinuation. The application was subsequently withdrawn in March 2026. This monograph reviews the chemistry, structural class, and synthesis of blarcamesine; the sigma-1 receptor and muscarinic receptor pharmacology; the pharmacokinetic profile including the ANAVEX19-144 metabolite; the preclinical evidence base across Alzheimer’s, Rett syndrome, fragile X syndrome, and Parkinson’s disease models; the full clinical evidence base; sourcing considerations; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five sigma-1 receptor-active compounds against blarcamesine on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Selective M1 muscarinic acetylcholine receptor partial agonist of the tetrahydropyrimidine-oxadiazole structural class
A functionally selective partial agonist at the M1 muscarinic acetylcholine receptor developed at the University of Toledo as a cognitive enhancer and neuroprotective agent for Alzheimer’s disease, distinguished from earlier muscarinic agonists by subtype selectivity, low cholinergic adverse-event burden, and oral bioavailability.
Abstract
CDD-0102, the hydrochloride salt of 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (designated CDD-0102A in its salt form), is a functionally selective partial agonist at the M1 subtype of the muscarinic acetylcholine receptor developed at the University of Toledo College of Pharmacy under the direction of W.S. Messer Jr. as a candidate therapeutic for Alzheimer’s disease and related cognitive disorders. The compound occupies the orthosteric acetylcholine-binding site of the M1 receptor with partial agonist intrinsic activity sufficient to activate phospholipase C-coupled signaling, stimulate non-amyloidogenic processing of amyloid precursor protein (APP) through alpha-secretase, and enhance cognitive function in rodent models of cholinergic deficit, while exhibiting minimal functional activity at M2, M4, and M5 muscarinic subtypes and only weak activity at M3 receptors. This functional selectivity profile distinguishes CDD-0102 from the first-generation M1-preferring muscarinic agonists (xanomeline, sabcomeline, talsaclidine, cevimeline) that produced dose-limiting cholinergic adverse events (salivation, gastrointestinal disturbance, diaphoresis) attributable to activation of peripheral M2 and M3 receptors, a limitation that terminated or constrained the clinical development of each of those compounds in the Alzheimer’s indication. The pharmacological characterization of CDD-0102 encompasses M1-selective receptor binding, stimulation of soluble APP-alpha (sAPPalpha) secretion from Chinese hamster ovary cells stably expressing human M1 receptors, neuroprotective activity in cell culture, brain penetration following systemic administration in rodents, oral bioavailability, and a favorable acute toxicity profile. In behavioral pharmacology, CDD-0102A administered intraperitoneally at doses of 0.03 to 1.0 mg/kg enhances delayed spontaneous alternation in a four-arm cross maze (a measure of spatial working memory) and facilitates strategy switching between place and visual-cue discriminations (a measure of cognitive flexibility), with both effects following a dose-dependent profile and occurring at doses below the threshold for salivation (approximately 0.3 mg/kg intraperitoneal for the minimum effective salivation dose, with an estimated ED50 for salivation of 2.0 mg/kg). More recent preclinical work has extended the pharmacological profile to autism spectrum disorder models, demonstrating that CDD-0102A attenuates stereotyped motor behaviors (self-grooming, digging) and modulates glutamate efflux in dorsolateral striatum of the BTBR T+ Itpr3tf/J mouse, a model of autism-relevant repetitive behavior and social deficit. The compound advanced through preclinical development with support from the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, which funded the IND-enabling studies including synthetic scale-up, formulation, pharmacokinetics, and toxicology. An Investigational New Drug (IND) application was filed with the United States Food and Drug Administration, and Phase 1 clinical testing was initiated. Published results from Phase 1 clinical evaluation have not appeared in the peer-reviewed literature as of the most recent monograph revision. The compound is not registered as a marketed medicine in any jurisdiction. This monograph reviews the chemistry, synthesis, and structural class of CDD-0102; the M1 muscarinic receptor pharmacology in molecular and functional detail; the preclinical evidence base across Alzheimer’s disease, cognitive flexibility, and autism-relevant endpoints; the available pharmacokinetic characterization; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety profile; and a comparative assessment of five M1 muscarinic receptor agonist candidates (xanomeline, sabcomeline, talsaclidine, AF267B, cevimeline) against CDD-0102 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Urolithin A is a natural compound produced by gut bacteria from pomegranate, walnuts, and berries. It induces mitophagy, the process of cleaning out damaged mitochondria. Amazentis sells a clinical-grade form as Mitopure. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Dibenzo[b,d]pyranone mitophagy inducer derived from gut microbial metabolism of dietary ellagitannins
A naturally occurring benzo[c]chromenone produced by human gut microbiota from ellagitannin precursors, identified as the first dietary metabolite to induce mitophagy through the PINK1/Parkin pathway in human skeletal muscle at oral doses, with clinical evidence in age-related mitochondrial decline, muscle function, immune senescence, and emerging neuroprotective applications.
Abstract
Urolithin A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one) is a dibenzopyranone metabolite produced by the human gut microbiota through sequential dehydroxylation of ellagic acid, itself the hydrolysis product of dietary ellagitannins found in pomegranates, walnuts, raspberries, and strawberries. The compound was first characterized as a bioactive ellagitannin metabolite in human plasma and urine by the Tomas-Barberan and Espin laboratories at CEBAS-CSIC (Murcia, Spain) in the early 2000s and was subsequently identified by the Auwerx laboratory at the Ecole Polytechnique Federale de Lausanne (EPFL) as a potent, first-in-class inducer of mitophagy in Caenorhabditis elegans and in mammalian systems through the PINK1/Parkin-dependent mitochondrial quality control pathway. The seminal Ryu et al. (2016) report in Nature Medicine demonstrated that urolithin A extends lifespan in C. elegans, improves exercise capacity in aged rodents, and induces a molecular signature of mitophagy in skeletal muscle, establishing the compound as the first dietary metabolite with demonstrated mitophagy-inducing activity at physiologically achievable concentrations [1]. Amazentis SA (Lausanne, Switzerland) subsequently developed a synthetic, pharmaceutical-grade form of urolithin A (marketed as Mitopure) and advanced the compound through a series of randomized, placebo-controlled clinical trials in human subjects. The first-in-human trial (Andreux et al. 2019, Nature Metabolism) demonstrated safety, oral bioavailability, and upregulation of mitochondrial gene expression in skeletal muscle of 60 healthy elderly subjects at doses of 250 to 2000 mg administered over 28 days [2]. A subsequent four-month randomized trial in 88 middle-aged adults (Singh et al. 2022, Cell Reports Medicine) demonstrated significant improvement in muscle strength (approximately 12 percent increase in hamstring muscle strength) and exercise performance at 500 mg and 1000 mg daily doses, with concurrent improvement in plasma biomarkers of mitochondrial health [3]. A parallel randomized trial (Liu et al. 2022, JAMA Network Open) in 66 older adults confirmed improvement in muscle endurance at 1000 mg daily over four months [4]. Most recently, a 2025 randomized trial (Singh et al. 2025, Nature Aging) in 50 healthy middle-aged adults demonstrated that 1000 mg daily urolithin A for four weeks expanded peripheral naive-like CD8+ T cell populations, reduced markers of T cell exhaustion, and increased CD8+ fatty acid oxidation capacity, establishing the first clinical evidence of urolithin A activity on immune senescence [5]. The molecular pharmacology of urolithin A extends beyond mitophagy induction to include activation of AMP-activated protein kinase (AMPK), inhibition of mechanistic target of rapamycin (mTOR), activation of sirtuin 1 (SIRT1) with consequent deacetylation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) to promote mitochondrial biogenesis, suppression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling with reduction of proinflammatory cytokines, and inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) relevant to Alzheimer’s disease pathology. Pharmacokinetics in humans are characterized by intestinal absorption followed by extensive hepatic phase II conjugation (glucuronidation and sulfation), producing circulating glucuronide and sulfate conjugates with peak plasma concentrations at approximately 6 to 8 hours and elimination half-lives of 17 to 24 hours for the predominant glucuronide species. The compound received Generally Recognized as Safe (GRAS) status from the United States Food and Drug Administration in 2018 (GRN 000791) at dietary intake levels up to 1000 mg per serving. Preclinical safety assessment established a no-observed-adverse-effect level (NOAEL) of 3451 mg/kg/day in male rats and 3826 mg/kg/day in female rats in a 90-day oral toxicity study, with no evidence of genotoxicity or mutagenicity. This monograph reviews the chemistry, endogenous biosynthesis, and chemical synthesis of urolithin A; the multi-target molecular pharmacology encompassing mitophagy, mitochondrial biogenesis, anti-inflammatory, and neuroprotective mechanisms; the human pharmacokinetic profile including interindividual variability driven by gut microbiome metabotype; the clinical evidence base across muscle function, immune health, and emerging neurodegenerative and cardiometabolic indications; sourcing and quality verification for research applications; reconstitution and handling; stack interaction considerations; adverse-event profile; and a structured comparative assessment of five mitochondrial-targeted compounds against urolithin A on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
NQO1-bioactivatable ortho-naphthoquinone with selective tumor cytotoxicity through futile redox cycling and PARP1 hyperactivation
A naturally derived 1,2-naphthoquinone from the lapacho tree, bioactivated selectively by NAD(P)H:quinone oxidoreductase 1 to induce tumor-specific programmed necrosis through futile redox cycling, massive reactive oxygen species generation, DNA damage, PARP1 hyperactivation, and catastrophic NAD+/ATP depletion.
Abstract
Beta-lapachone is a naturally occurring ortho-naphthoquinone originally isolated from the heartwood of Tabebuia avellanedae (pau d’arco, lapacho) and synthesized from the prenylated naphthoquinone lapachol by acid-catalyzed cyclization. The compound is the canonical substrate of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2), a two-electron reductase that is overexpressed 5- to 100-fold in the majority of solid human cancers, including non-small cell lung, pancreatic ductal adenocarcinoma, breast, prostate, and head and neck squamous cell carcinomas, relative to matched normal tissue. NQO1-mediated two-electron reduction of beta-lapachone produces an unstable hydroquinone that spontaneously autoxidizes back to the parent quinone in a futile redox cycle consuming approximately 60 moles of NAD(P)H per mole of drug over a 2-hour exposure window. This cycle generates massive superoxide and hydrogen peroxide fluxes within the tumor cell, producing extensive oxidative DNA damage (predominantly single-strand breaks and oxidized bases) that triggers hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) in the presence of elevated nuclear calcium. PARP1 hyperactivation consumes the cellular NAD+ pool into branched poly(ADP-ribose) polymers, producing catastrophic NAD+ and ATP depletion, mu-calpain activation, apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus, and programmed necrosis that is mechanistically distinct from classical apoptosis and independent of caspase activation, p53 status, and Bcl-2 family protein expression. The NQO1 dependence of the cytotoxic mechanism confers tumor selectivity: NQO1-negative cells (including most normal tissues) are resistant to beta-lapachone at pharmacologically achievable concentrations, and dicoumarol (an NQO1 inhibitor) completely abrogates cytotoxicity in NQO1-positive cancer cell lines. Beta-lapachone was advanced into clinical development as ARQ 501 (an intravenous hydroxypropyl-beta-cyclodextrin inclusion complex) by ArQule, Inc. and subsequently as ARQ 761 (an improved intravenous formulation) by the University of Texas Southwestern Medical Center. Phase I trials in patients with advanced solid tumors established a maximum tolerated dose of 390 mg/m2 as a 2-hour intravenous infusion every other week, with dose-limiting toxicities of hemolytic anemia and methemoglobinemia attributable to off-target redox cycling interaction with cytochrome b5 reductase in erythrocytes. A Phase II trial of ARQ 501 in combination with gemcitabine in treatment-naive unresectable pancreatic adenocarcinoma demonstrated disease stabilization but did not produce objective tumor responses sufficient for registration. A separate clinical derivative, MB12066, was developed for metabolic syndrome indications and completed first-in-human pharmacokinetic and tolerability studies at oral doses of 10 to 400 mg. Beyond anticancer applications, beta-lapachone exhibits anti-inflammatory activity through suppression of NF-kappaB-driven cytokine expression in activated macrophages and microglia, anti-obesity effects through stimulation of energy expenditure and white adipose tissue browning via NQO1-dependent NADH oxidation, and antimicrobial activity against Trypanosoma cruzi and Mycobacterium tuberculosis. This monograph reviews the chemistry, synthesis, and natural product origin of beta-lapachone; the NQO1-dependent futile redox cycling mechanism in molecular detail; the comprehensive pharmacokinetic record including formulation challenges; the preclinical and clinical evidence base across oncology, metabolic, and inflammatory indications; the reconstitution, sourcing, and handling considerations for laboratory work; and a comparative assessment of five NQO1-targeted or naphthoquinone-class compounds against beta-lapachone on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory authority for any therapeutic indication. It is available as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Para-benzoquinone 15-lipoxygenase inhibitor and redox-active cytoprotectant derived from alpha-tocotrienol quinone
A synthetic vitamin E-derived para-benzoquinone developed by Edison Pharmaceuticals as a potent inhibitor of 15-lipoxygenase and augmenter of intracellular glutathione biosynthesis, advanced through clinical evaluation in Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other inherited mitochondrial respiratory chain diseases.
Abstract
EPI-743, now designated vatiquinone (INN) and previously referred to by the development codes PTC-743 and alpha-tocotrienol quinone, is a synthetic para-benzoquinone derived from the chromanone ring system of vitamin E (alpha-tocotrienol) that was identified in a phenotypic screen for small molecules capable of preventing oxidative cell death induced by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and therefore of de novo glutathione biosynthesis. The compound is approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease and Friedreich ataxia patient fibroblasts in oxidative stress assays, a potency differential attributed to its capacity to serve as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) and thereby to replenish reduced intracellular glutathione and stabilize cellular redox balance. The mechanistic target has subsequently been identified as 15-lipoxygenase (15-LO), an oxidoreductase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids under conditions of glutathione depletion or glutathione peroxidase 4 (GPX4) inactivation, a process now recognized as the lipid peroxidation arm of ferroptotic cell death. Vatiquinone is therefore classified as a first-in-class selective inhibitor of 15-lipoxygenase with secondary redox-modulatory activity through NQO1-dependent glutathione replenishment. The compound was discovered at Edison Pharmaceuticals (Mountain View, California), a company founded by Guy Miller and subsequently renamed BioElectron Technology Corporation in 2017. PTC Therapeutics acquired substantially all of BioElectron’s assets, including the vatiquinone program, in October 2019 for approximately $210 million. The clinical development program has spanned multiple inherited mitochondrial diseases and related conditions characterized by oxidative stress, mitochondrial dysfunction, and ferroptotic cell death. Open-label and emergency-protocol studies conducted between 2011 and 2017 evaluated EPI-743 in Leigh syndrome (Martinelli et al. 2012, ten pediatric patients, statistically significant reversal of disease progression on the Newcastle Pediatric Mitochondrial Disease Scale), in Leber hereditary optic neuropathy (Sadun et al. 2012, five patients, arrest of disease progression and reversal of visual loss in four of five subjects), in a heterogeneous cohort of genetically confirmed mitochondrial respiratory chain diseases (Enns et al. 2012, fourteen patients, clinical improvement in eleven of twelve survivors), and in Pearson syndrome. A Phase 2 study in Friedreich ataxia demonstrated safety and tolerability over two years. The pivotal registration-directed program is the Phase 3 MOVE-FA trial, a randomized, placebo-controlled, 72-week study in 146 pediatric and adult patients with Friedreich ataxia. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population (p = 0.14), though statistically significant effects were observed on the pre-specified upright stability subscale (p = 0.021) and in the per-protocol population (p < 0.05). Long-term extension data demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry at 144 weeks, representing a 50 percent slowing of disease progression over three years. PTC Therapeutics submitted a New Drug Application to the United States Food and Drug Administration, which granted Priority Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter, indicating that additional efficacy data would be required to support approval. Pharmacokinetics are characterized by oral absorption with an effective half-life of approximately 9 hours, dose-proportional exposure across oral doses of 200 to 1,400 mg, CYP3A4-mediated hepatic metabolism, and lipophilic distribution consistent with the vitamin E-derived chemical structure. The compound is administered three times daily with food to enhance bioavailability. The safety profile across more than 500 patients and treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies. This monograph reviews the chemistry, synthesis, and structural pharmacology of EPI-743; the 15-lipoxygenase inhibition and NQO1-dependent redox mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other mitochondrial diseases; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative mitochondrial cytoprotectant or antioxidant compounds (idebenone, omaveloxolone, coenzyme Q10, elamipretide, and alpha-tocopherol) against EPI-743 on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity
A cell-permeable tricyclic pyranopyrone synthesized at Kansas State University as an anti-amyloidogenic agent, subsequently characterized as a mild inhibitor of mitochondrial complex I that activates AMPK-dependent neuroprotective signaling, crosses the blood-brain barrier, and reduces amyloid-beta, phosphorylated tau, oxidative stress, and neuroinflammation in multiple transgenic mouse models of familial Alzheimer’s disease.
Abstract
CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3′ nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. Chronic oral administration at 25 mg/kg/day in drinking water in multiple transgenic mouse models of familial Alzheimer’s disease (Tg2576, 3xTg-AD, APP/PS1, 5xFAD) has produced consistent reductions in amyloid-beta and phosphorylated tau accumulation, oxidative stress, neuroinflammation, and cognitive dysfunction, while improving mitochondrial function, energy homeostasis, synaptic activity, dendritic spine density and morphology, and long-term potentiation in the hippocampus [5, 7, 8, 9]. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer’s disease to Huntington’s disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer’s disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, synthesis, and stereochemistry of CP2; the dual mechanism of action encompassing direct amyloid-beta binding and mild mitochondrial complex I inhibition; the pharmacokinetic profile in rodents; the preclinical evidence base across Alzheimer’s disease and Huntington’s disease models; sourcing and handling considerations for laboratory use; stack interaction considerations; the adverse event and safety signal from preclinical data; and a comparative assessment of five mitochondrial-targeted or anti-amyloidogenic neuroprotective candidates against CP2 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory agency and is not registered as a medicine in any jurisdiction. It is supplied as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Flavonoid-derived carbamate prodrug of 7,8-dihydroxyflavone with selective tropomyosin receptor kinase B agonist activity
A rationally designed bis-carbamate prodrug of 7,8-dihydroxyflavone engineered for improved oral bioavailability and sustained brain-derived neurotrophic factor receptor activation, advancing through Phase 1 clinical evaluation for Alzheimer’s disease and under preclinical investigation for amyotrophic lateral sclerosis, depression, Parkinson’s disease, and peripheral nerve regeneration.
Abstract
R-13 (BrAD-R13, Braegen-01) is a synthetic bis-methylcarbamate prodrug of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin), designed to overcome the poor oral bioavailability and rapid hepatic conjugation of the parent flavone while preserving its selective agonist activity at the tropomyosin receptor kinase B (TrkB) receptor, the principal high-affinity signaling receptor for brain-derived neurotrophic factor (BDNF). The compound was identified through systematic medicinal chemistry optimization of ester and carbamate modifications on the 7,8-DHF catechol ring by Chen, Ye, and colleagues at Emory University School of Medicine and Zhejiang University, with R-13 selected from among twenty candidate derivatives as the sole compound satisfying all screening criteria for gastric acid stability, intestinal absorption, hydrolyzability in liver microsomes and plasma, and adequate membrane permeability. Following oral administration, R-13 is hydrolyzed through a monophenol intermediate (designated T1) to release 7,8-DHF, which binds the extracellular domain of TrkB and triggers receptor dimerization, autophosphorylation, and activation of the downstream Akt and ERK/MAPK signaling cascades. In mice, R-13 at 36 mg/kg oral dose produces a maximum plasma concentration of 129 ng/mL at 30 minutes, with an elimination half-life of approximately 220 minutes and oral bioavailability of 10.5 percent (compared to 4.6 percent for the parent 7,8-DHF), and sustains brain 7,8-DHF concentrations above 8 ng/g for at least 4 hours. The pharmacological consequences of sustained TrkB activation are broad: R-13 represses asparagine endopeptidase (AEP, also termed delta-secretase), a protease implicated in the pathological cleavage of both amyloid precursor protein and tau in Alzheimer’s disease, thereby reducing amyloid-beta deposition and neurofibrillary tangle formation. Chronic oral administration of R-13 in the 5XFAD transgenic mouse model of Alzheimer’s disease dose-dependently restored dendritic spine density, enhanced long-term potentiation, reduced senile plaque burden, attenuated neuroinflammatory cytokine levels (interleukin-1-beta, interleukin-6, tumor necrosis factor alpha), and reversed spatial and working memory deficits in the Morris water maze without demonstrable toxicity at 12 weeks of continuous dosing at up to 43.6 mg/kg/day. Additional preclinical evidence supports efficacy in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis, where R-13 preserved motor neuron counts, reduced gastrocnemius muscle atrophy, attenuated glial activation, and enhanced mitochondrial biogenesis through AMPK/PGC-1-alpha/Nrf1/Tfam pathway activation. In a peripheral nerve transection model, oral R-13 produced axon regeneration and functional electromyographic recovery superior to the parent 7,8-DHF. R-13 has also been characterized as preventing ovariectomy-induced bone loss through TrkB/Akt-mediated inhibition of AEP and upregulation of osteoprotegerin. Braegen Pharmaceutical (Shenzhen, China) has completed a Phase 1 clinical trial of BrAD-R13 in Alzheimer’s disease, the first clinical evaluation of a TrkB agonist prodrug in this indication, with plans for Phase 2 efficacy trials. The compound is not approved in any jurisdiction for any indication. This monograph reviews the chemistry, synthesis, and prodrug design of R-13; the TrkB receptor pharmacology and downstream signaling; the comprehensive preclinical pharmacokinetic profile; the evidence base across Alzheimer’s disease, amyotrophic lateral sclerosis, peripheral nerve injury, bone metabolism, and neuropsychiatric indications; sourcing and handling for research applications; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative TrkB agonist and BDNF-mimetic candidates against R-13 on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
MitoQ is mitochondria-targeted ubiquinone (a derivative of CoQ10 with a positively charged triphenylphosphonium group that drives accumulation in mitochondria). Concentrates antioxidant activity at the mitochondrial inner membrane where oxidative damage occurs. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Mitochondria-targeted ubiquinone-derived antioxidant conjugated to a triphenylphosphonium cation
A synthetic coenzyme Q10 analog covalently linked to a lipophilic triphenylphosphonium moiety that drives selective mitochondrial accumulation, enabling targeted quenching of reactive oxygen species at the inner mitochondrial membrane with demonstrated vascular, hepatoprotective, and anti-inflammatory activity in human clinical studies.
Abstract
Mitoquinone mesylate (MitoQ) is a mitochondria-targeted antioxidant composed of a ubiquinone moiety covalently linked via a ten-carbon alkyl chain to a triphenylphosphonium (TPP+) cation, enabling rapid permeation of lipid bilayers and accumulation within the mitochondrial matrix at concentrations up to several hundred-fold above extracellular levels, driven by the large negative mitochondrial membrane potential (approximately negative 150 to negative 180 millivolts). The compound was developed in the 1990s by Robin Smith and Michael Murphy at the University of Otago, New Zealand, as an approach to overcoming the failure of conventional untargeted antioxidants (including native coenzyme Q10) to achieve therapeutically meaningful concentrations within mitochondria, the principal intracellular source of reactive oxygen species (ROS). Within the mitochondrion, MitoQ adsorbs to the matrix-facing leaflet of the inner mitochondrial membrane, where the ubiquinone head group is reduced to the active antioxidant ubiquinol form by complex II (succinate:ubiquinone oxidoreductase) of the electron transport chain. The ubiquinol form scavenges superoxide, hydroxyl radicals, and peroxyl radicals, preventing lipid peroxidation of cardiolipin and other mitochondrial membrane phospholipids. Following oxidation during radical quenching, the resulting ubiquinone is re-reduced by complex II, establishing a catalytic antioxidant cycle that permits repeated radical neutralization from a single molecule. This recycling mechanism distinguishes MitoQ from stoichiometric antioxidants such as alpha-tocopherol that are consumed in the quenching reaction. Preclinical pharmacology has demonstrated protective effects in rodent models of ischemia-reperfusion injury, diabetic nephropathy, nonalcoholic fatty liver disease, sepsis-associated organ failure, pulmonary hypertension, Alzheimer’s disease, doxorubicin-induced cardiomyopathy, cisplatin nephrotoxicity, and metabolic syndrome, with consistent reductions in mitochondrial oxidative damage markers, preservation of mitochondrial membrane potential, and attenuation of downstream inflammatory signaling through suppression of NF-kappaB activation and NLRP3 inflammasome assembly. Four completed human clinical trials define the current clinical evidence base. The Snow et al. (2010) PROTECT study, a 12-month randomized double-blind placebo-controlled trial in 128 newly diagnosed untreated Parkinson’s disease patients at 40 or 80 mg per day, found no difference between MitoQ and placebo on any measure of disease progression, establishing an important negative result for the oxidative stress hypothesis in early Parkinson’s disease. The Gane et al. (2010) phase II trial in 30 patients with chronic hepatitis C virus infection demonstrated significant decreases in serum alanine aminotransferase and aspartate aminotransferase at 40 and 80 mg per day over 28 days, without change in viral load, suggesting hepatoprotective activity through reduction of mitochondrial oxidative necroinflammation. The Rossman et al. (2018) randomized crossover trial in 20 healthy older adults (60 to 79 years) with impaired endothelial function demonstrated that 6 weeks of MitoQ at 20 mg per day produced a 42 percent improvement in brachial artery flow-mediated dilation versus placebo, with concurrent reductions in plasma oxidized low-density lipoprotein and aortic pulse wave velocity, establishing the first human evidence for mitochondria-targeted antioxidant improvement of age-related vascular dysfunction. A 2024 exploratory pilot trial (Jain et al. 2024) of MitoQ as post-exposure prophylaxis against SARS-CoV-2 infection reported reduced infection rates and symptom duration in the treatment group versus matched controls. The compound is well tolerated in human studies at doses up to 80 mg per day for 12 months, with nausea and gastrointestinal discomfort as the principal dose-limiting adverse events. MitoQ is not approved as a pharmaceutical by any regulatory authority; it is marketed globally as a dietary supplement at doses of 5 to 10 mg per day and is available as a research-grade compound from multiple chemical suppliers. This monograph reviews the chemistry, synthesis, and mitochondrial targeting mechanism of MitoQ; the comprehensive preclinical pharmacology across disease models; the complete human clinical evidence base; pharmacokinetics including the low oral bioavailability and extensive first-pass metabolism; sourcing, reconstitution, and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates (SkQ1, elamipretide, MitoTEMPO, MitoVitE, idebenone) against MitoQ on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Fisetin is a natural flavonoid found in strawberries and apples that selectively kills senescent cells (a senolytic). Mayo Clinic researchers identified it in screens looking for natural compounds with senolytic activity. Clinical trials are ongoing. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Flavonol polyphenol with senolytic, anti-inflammatory, and neuroprotective activity
A naturally occurring 3,7,3′,4′-tetrahydroxyflavone identified as one of the most potent flavonoid senolytics, with convergent activity across PI3K/Akt/mTOR inhibition, SIRT1 activation, NF-kappaB suppression, and Nrf2-mediated antioxidant defense, positioned at the intersection of aging biology, neurodegeneration, and cancer chemoprevention research.
Abstract
Fisetin (3,7,3′,4′-tetrahydroxyflavone) is a bioactive flavonol found at highest dietary concentration in strawberries and at lower levels in apples, persimmons, grapes, onions, and cucumbers. First isolated from the heartwood of Venetian sumac (Cotinus coggygria) in the late nineteenth century and characterized as a plant pigment, fisetin remained a minor flavonoid of limited pharmacological interest until convergent twenty-first-century discoveries established it as a multi-target agent active across the principal molecular pathways of cellular senescence, neurodegeneration, inflammation, and oncogenesis. The compound was identified as a potent senolytic in the landmark Zhu et al. (2017) screen at the Mayo Clinic Robert and Arlene Kogod Center on Aging, and the subsequent Yousefzadeh et al. (2018) demonstration that late-life oral fisetin administration extended median and maximum lifespan in wild-type mice while reducing senescence-associated markers in multiple tissues positioned it as the leading dietary flavonoid candidate for translational senolytic therapy [1, 2]. Mechanistically, fisetin operates through a convergent multi-pathway pharmacology: it inhibits PI3K/Akt/mTOR signaling by direct suppression of PI3K catalytic and regulatory subunit expression and by activation of the mTOR repressor TSC2 through concurrent AMPK phosphorylation; it activates SIRT1-dependent deacetylation cascades that suppress NF-kappaB transcriptional activity and the senescence-associated secretory phenotype (SASP); it induces Nrf2 nuclear translocation and downstream phase II antioxidant enzyme expression; and it modulates the Bcl-2 family balance toward pro-apoptotic signaling selectively in senescent cells [3, 4, 5]. The neuroprotective profile has been extensively characterized by the Maher laboratory at the Salk Institute for Biological Studies, where fisetin and its optimized derivative CMS121 have demonstrated efficacy in transgenic Alzheimer’s disease mouse models through reduction of lipid peroxidation via fatty acid synthase (FASN) inhibition, suppression of neuroinflammatory cascades, and maintenance of glutathione homeostasis [6, 7]. CMS121 completed a Phase 1 clinical trial in 2025, with single doses up to 1800 mg and repeat doses up to 900 mg per day for 7 days demonstrating acceptable tolerability and favorable pharmacokinetic parameters in healthy volunteers [8]. The anticancer pharmacology spans preclinical efficacy in prostate, breast, colorectal, lung, melanoma, pancreatic, and bladder cancer models, principally through cell cycle arrest at G2/M and G1/S checkpoints, mitochondrial apoptosis induction, and suppression of epithelial-mesenchymal transition and matrix metalloproteinase expression [9, 10]. Clinical translation is constrained by the poor oral bioavailability characteristic of hydroxylated flavonols: fisetin undergoes rapid and extensive phase II conjugation (glucuronidation and sulfation) in the intestinal epithelium and liver, producing low systemic free flavonol concentrations after oral dosing; multiple formulation strategies (nanocochleates, liposomes, nanoemulsions, hybrid hydrogels) have demonstrated 10- to 140-fold bioavailability enhancement in preclinical and early human pharmacokinetic studies [11, 12]. Clinical trials led by the Kirkland laboratory at Mayo Clinic are evaluating fisetin at oral doses of 20 mg/kg per day for senolytic indications including frailty in aging (AFFINITY trial, NCT03675724), COVID-19 in skilled nursing facilities, and sepsis in elderly patients (STOP-Sepsis, NCT05758246) [13, 14]. This monograph reviews the chemistry, natural sourcing, and structural pharmacology of fisetin; the multi-pathway molecular mechanism across senescence, inflammation, neuroprotection, and oncogenesis; the pharmacokinetic limitations and formulation solutions; the preclinical evidence base across aging, neurodegeneration, and cancer; the clinical trial landscape; sourcing and quality verification for research applications; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five senolytic or flavonoid candidates against fisetin on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
